Dimethyl Sulfoxide
Apexbio Technology LLC Aurora A Inhibitor I 1158838-45-9 10mM (in 1mL DMSO)
Aurora A Inhibitor I (CAS 1158838-45-9) is a selective and potent small-molecule inhibitor of Aurora A kinase exhibiting an IC50 of 3 4 nM Aurora kinases are serine/threonine kinases crucially involved in mitotic progression with Aurora A specifically implicated in centrosome maturation and spindle assembly Aurora A Inhibitor I exerts high specificity significantly favoring Aurora A over Aurora B or cyclin-dependent kinases (CDKs) in vitro Subtle amino acid changes within kinase active sites significantly impact inhibitor potency highlighting residue-dependent selectivity This compound represents a valuable research tool for investigating Aurora A-related signaling pathways and their roles in cell division and oncogenesis
Apexbio Technology LLC HATU 148893-10-1 10mM (in 1mL DMSO)
HATU (1-[Bis(dimethylamino)methylene]-1H-1 2 3-triazolo[4 5-b]pyridinium 3-oxid hexafluorophosphate) is a peptide coupling reagent routinely employed for amide-bond formation in peptide synthesis and other biomolecular applications In solution HATU converts carboxylic acids into active ester intermediates (OAt esters) facilitating subsequent nucleophilic attack from amines or alcohols This reaction typically proceeds in presence of basic additives such as N N-Diisopropylethylamine (DIPEA) under anhydrous conditions in solvents like dimethylformamide (DMF) Its utility extends to synthesizing peptides and modifying biomolecules through ester or amide linkage formation widely applied in biomedical research and pharmaceutical laboratories
Apexbio Technology LLC Dexlansoprazole 138530-94-6 10mM (in 1mL DMSO)
Dexlansoprazole (CAS 138530-94-6) is the dextrorotatory isomer of lansoprazole classified pharmacologically as a proton pump inhibitor (PPI) It exerts its pharmacological effects by selectively inhibiting the gastric H /K -ATPase enzyme system thereby reducing gastric acid secretion Its dual delayed-release formulation facilitates prolonged acid suppression which has been investigated extensively for therapeutic utility in acid-related gastrointestinal disorders including gastroesophageal reflux disease (GERD) erosive esophagitis and associated conditions
Apexbio Technology LLC INK 128 (MLN0128) 1224844-38-5 10mM (in 1mL DMSO)
INK 128 (MLN0128 CAS 1224844-38-5) is a selective inhibitor of the mammalian target of rapamycin (mTOR) a conserved serine/threonine kinase integral to the PI3K/AKT/mTOR signaling pathway This compound inhibits both mTOR complexes (mTORC1 and mTORC2) demonstrating an IC50 of approximately 1 nM In preclinical studies utilizing human pancreatic and HER2-positive breast cancer cell lines INK 128 significantly reduced cellular proliferation and viability via concentration- and time-dependent suppression of mTOR activity Moreover it exhibited notable tumor suppression in breast cancer xenograft models enhancing efficacy when combined with agents such as sorafenib sunitinib paclitaxel or lapatinib highlighting its potential value for oncology research and therapeutic development
Supply Solutions Dimethyl sulfoxide, 67-68-5, MFCD00002089, 100mL
Linear Formula (CH3)2SO, Molecular Weight 78.13, bp 189 C (lit.), mp 16-19 C (lit.), for molecular biology, Synonym: DMSO
TARGETMOL CHEMICALS INC TRAMETINIB DMSO SOLVATE 200MG
Also available in 10 mg 25 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a Highly Potent and Selective MEK Inhibitor that specifically inhibits MEK1/2(IC50 2 nM)purity: 99%
Apexbio Technology LLC Entinostat (MS-275,SNDX-275) 209783-80-2 10mM (in 1mL DMSO)
Entinostat (MS-275 SNDX-275 CAS 209783-80-2) is an orally bioavailable small molecule inhibitor targeting histone deacetylases (HDACs) a family of enzymes involved in transcriptional regulation by modifying histone acetylation Specifically entinostat exhibits inhibitory activity against class I HDAC enzymes HDAC1 HDAC3 and HDAC8 with reported IC50 values of 0 368 M 0 501 M and 63 4 M respectively In preclinical investigations entinostat demonstrates anti-proliferative effects in diverse human tumor cell lines including breast colon lung multiple myeloma ovarian pancreatic prostate cancers and leukemia Due to these properties entinostat is widely utilized in oncology research
Apexbio Technology LLC Hesperadin 422513-13-1 10mM (in 1mL DMSO)
Hesperadin is a small-molecule ATP-competitive inhibitor targeting Aurora B kinase a serine/threonine-protein kinase involved in mitotic regulation By occupying the ATP-binding pocket of Aurora B and adjacent hydrophobic regions Hesperadin suppresses kinase activity with an IC50 approximately 250 nM In mitotic cells Aurora B-mediated phosphorylation of histone H3 Ser-10 is inhibited by Hesperadin this phosphorylation event is widely utilized as a mitotic biomarker Furthermore experimental applications of Hesperadin include investigating cell-cycle dynamics chromosome alignment and spindle checkpoint mechanisms as evidenced by its ability to disrupt proper chromosome alignment and segregation at approximately 40 nM IC50
Apexbio Technology LLC ARN-509 956104-40-8 10mM (in 1mL DMSO)
ARN-509 is a synthetic biaryl thiohydantoin derivative acting as a competitive inhibitor of the androgen receptor (AR) It binds AR with an IC50 of approximately 16 nmol/L blocking receptor-mediated signaling pathways implicated in prostate cell proliferation Androgen receptor is a nuclear hormone receptor crucial for male sexual differentiation and prostate cancer cell growth Overexpression or hyperactivation of AR frequently occurs in castration-resistant prostate cancer Experimental data indicate that ARN-509 treatment reduces AR-driven transcription and inhibits cell proliferation in prostate cancer cell lines such as LNCaP and VCaP In murine xenograft models oral dosing of ARN-509 diminishes androgen-dependent reporter gene activity reduces tumor cell proliferation and induces apoptosis ARN-509 is utilized in biomedical research to investigate AR signaling and prostate cancer therapeutics
Apexbio Technology LLC Mesna 19767-45-4 10mM (in 1mL DMSO)
Mesna chemically classified as a sulfhydryl-containing compound functions primarily as a protective adjuvant during chemotherapy with oxazaphosphorine agents (such as cyclophosphamide and ifosfamide) Its mode of action involves direct binding and detoxification of urotoxic metabolites notably acrolein thereby facilitating their conversion into stable non-toxic derivatives and mitigating associated bladder toxicity Due to this detoxifying effect Mesna is widely utilized in oncology research and clinical studies investigating chemotherapy-induced urotoxicity prevention Additionally given its structural feature as a thiol donor Mesna finds applications in experimental studies exploring its antioxidant activity and potential cytoprotective effects
Apexbio Technology LLC Rucaparib (AG-014699,PF-01367338) 459868-92-9 10mM (in 1mL DMSO)
Rucaparib (AG-014699 PF-01367338 CAS 459868-92-9) is a small molecule inhibitor targeting poly(ADP-ribose) polymerase (PARP) a nuclear enzyme activated by DNA damage and central to the base excision repair pathway By blocking PARP activity rucaparib impairs DNA repair especially in cells with pre-existing DNA repair deficiencies such as those induced by genotoxic stress In prostate cancer research rucaparib induces radiosensitization notably in PTEN-deficient cells expressing ETS fusion proteins through inhibition of non-homologous end joining (NHEJ) It is thus relevant in studies investigating DNA damage response pathways cancer biology and therapeutic radiosensitization strategies
Sigma Aldrich Fine Chemicals Biosciences CryoSOfreeTM DMSO free Cry
We are committed to bringing you Greener Alternative Products which adhere to one or more of The 12 Principles of Greener Chemistry. This product has Inherently Safer Chemistry compared to the standard use of DMSO for cryopreservation of cell cultures. for more information see here.
Apexbio Technology LLC LY2228820 862507-23-1 10mM (in 1mL DMSO)
LY2228820 (CAS 862507-23-1) is a potent selective ATP-competitive small-molecule inhibitor targeting the and isoforms of p38 mitogen-activated protein kinase (MAPK) with reported IC50 values of 5 3 nM and 3 2 nM respectively By suppressing p38 MAPK signaling LY2228820 decreases phosphorylation of heat shock protein 27 (HSP27) induced by Bortezomib thereby elevating cytotoxic effects in multiple myeloma (MM) models Additionally it inhibits secretion of IL-6 by bone marrow mononuclear cells and stromal cells as well as secretion of MIP-1 by patient-derived MM cell subsets and osteoclast precursors In melanoma (B16-F10) and NSCLC (A549) xenograft murine models LY2228820 reduces phosphorylation of MK2 and slows tumor progression respectively highlighting its potential utility in oncology research
Apexbio Technology LLC EHT 1864(Synonyms: EHT-1864, EHT1864, RAC inhibitor EHT1864, Rac GTPase inhibitor EHT 1864), 10mM (in 1mL DMSO), CAS: 754240-09-0.
EHT 1864 (CAS 754240-09-0) is a small-molecule inhibitor targeting Rac family GTPases with strongest affinity and inhibitory activity toward Rac1 It interacts directly with Rac isoforms Rac1 Rac1b Rac2 and Rac3 exhibiting Kd values of approximately 40 nM 50 nM 60 nM and 250 nM respectively By disrupting nucleotide binding EHT 1864 blocks Rac1 activation and prevents the formation of active Rac1/PAK-RBD complexes thus inhibiting downstream cellular functions such as PDGF-stimulated lamellipodia formation and Rac1-mediated cellular transformation This compound serves as a valuable tool in cell biology research for studying Rac-dependent signaling pathways and cellular dynamics